Welcome to our dedicated page for Pacira Biosciences SEC filings (Ticker: PCRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pacira BioSciences filings document a life sciences company's financial results, governance actions, credit arrangements and manufacturing-related corporate events. Recent Form 8-K reports furnish quarterly and annual results for the commercial portfolio, including EXPAREL, ZILRETTA and iovera, and disclose the company's common stock listing on the Nasdaq Global Select Market under PCRX.
The filing record also covers board composition and committee appointments, non-employee director compensation, senior secured revolving credit facility terms, and exit or disposal activities associated with EXPAREL manufacturing efficiencies and large-scale production suites. These disclosures frame Pacira's capital structure, liquidity arrangements, operating costs, governance and product-manufacturing infrastructure.
Pacira BioSciences (PCRX) filed an 8-K on 9 July 2025 announcing a restructuring under Item 2.05. The company is shuttering its first-generation 45-liter manufacturing suite at its San Diego Science Center after commissioning two 200-plus-liter suites (Swindon 2021, San Diego 2024) that produce roughly 4× more bulk EXPAREL per batch and carry a lower cost structure.
The decision triggers a reduction in force of 71 employees, or ~8 % of head-count. Management expects to book $2.4 – $2.8 million in cash charges for severance, garden leave and related benefits plus $5.4 million of accelerated depreciation, with most of the impact flowing through Q3 2025 results.
Once complete, Pacira anticipates an annual operating-expense reduction of about $13 million and improved gross margins for EXPAREL owing to higher yields and scale efficiencies. The company cautions that additional, presently unforeseen, charges may arise and reiterates standard forward-looking-statement language.
An employee communication from CEO Frank D. Lee (Exhibit 99.1) was furnished under Item 7.01 and is not deemed filed. No changes were disclosed to current revenue guidance, product strategy or other financial metrics beyond the charges and cost-saving estimates.